Reply to Roy et al. Leukemia advance online publication, 14 July 2005. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. In their correspondence, 1 Roy et al. report that six among 189 CML patients treated with imatinib at their Institution developed a second malignancy. All of the patients had received interferon-based therapy before beginning imatinib therapy. The study reported that the appearance of second malignancies was potentially in accordance with the incidence of cancer in the French population, with the exception of prostate cancer, which was found in three patients. They reported this incidence to be higher than the expected incidence in a French population.
In November 2004 Novartis performed an epidemiological analysis of second primary malignancies among 9518 patients in our global database treated with imatinib during Novartis sponsored clinical trials as well as spontaneous adverse reports from approximately 124 000 patient years (PY) of treatment (unpublished observations, data on file Novartis). The objective was to compare the incidence rates of second cancers among patients treated with imatinib with the expected incidence based on the rates among the general population. In addition, the frequency of spontaneous reports of cancer associated with imatinib was analyzed based on cases collected in the clinical safety database. This analysis did not provide evidence for an increased overall incidence of malignancies or in the incidence of bladder, kidney or prostate tumors in patients treated with imatinib compared to that of an age adjusted general population.
In May 2005 Novartis updated the information on second malignancies as part of ongoing safety surveillance (unpublished observations, data on file Novartis). In all, 110 malignant neoplasms including 16 prostate ca, two urinary bladder ca and three kidney carcinomas, were reported up to May 10, 2005 in Novartis sponsored clinical trials of imatinib. The observed incidence rates were: 720.34 per 100 000 PY for all malignant cancers (excluding nonmelanoma skin cancer and malignancies representing progression of the underlying disease) and 262.01 per 100 000 PY for prostate cancer. To compare these with the incidence of cancer in the general population, standardized incidence ratios (SIRs) (i.e., ratios of observed to expected cases) standardized for gender and 5-year age groups were estimated, based on Surveillance, Epidemiology, and End Results (SEER) data (Surveillance, Epidemiology and End Results (SEER) Program (http://www.seer.cancer.gov)). The SIRs were 0.87 (95% CI 0.69-1.08) and 0.86 (95% CI 0.49-1.39) for all cancers and prostate cancer, respectively, showing that the numbers of cancers in the Novartis sponsored clinical trials are similar to those expected based on the rates in general population. This database continues to mature with a mean time-at-risk for the trial population of 1.16 years (0-4.91 years), defined as a period starting 4 weeks after the beginning of imatinib until the end of follow-up.
Roy et al. report that each of six patients at their Institution with a second malignancy was at least 60 years old. Specifically, among three patients who developed prostate cancer, two were 65 and one 69 years old. The authors calculated the incidence rate as 478.5 per 100 000 PY, compared it with incidence rates for age group 40-69 in France (region Bas-Rhin) for 1975-1977 (35.0 per 100 000) and for 1995-1997 (110.6 per 100 000) and concluded that the frequency of prostate cancer on imatinib is at least four times higher than expected. As stated in Quaglia et al. 2 prostate ca 'usually affects elderly subjects aged 65 years or more and is a rare disease before 50 years of age'. Incidence rates for prostate carcinoma increase dramatically with age: from 10.4 per 100 000 PY for the age group 40-49, through 118.7 for 50-59, and 507.5 for 60-69 years old men (average annual age-adjusted incidence rates in the US based on year of diagnosis 1992-2001: SEER) (Surveillance, Epidemiology and End Results (SEER) Program (http://www.seer.cancer.gov)). Thus, only a comparison of rates within relatively narrow age groups is scientifically justified. Although the majority of imatinib patients (69%) observed by Roy et al. were between 40 and 69 years old, the differentiation of incidence rates of prostate cancer in this age group precludes any valid comparison.
We would like to congratulate Roy et al. for monitoring their patient populations for ongoing and late side effects of therapy. Given the remarkable success imatinib has had in patients with CML, coupled with the necessity to continue therapy based on current results, we concur with the need for long-term monitoring of patients on imatinib for late effects. They also made reference to the investigator notification letter, which was sent on September 24, 2004 following the preliminary results coming from our 2 year preclinical carcinogenicity study performed in rats. To date, this preclinical information has not translated to a signal, we can detect in patients, but imatinib has been available to patients for less than a decade and close monitoring is called for. In keeping with the Company's commitment to ensure patient health and safety, Novartis will continue to monitor the long-term effects of treatment with imatinib, such as second malignancies, through ongoing clinical trials, as well as spontaneous reports from researchers and physicians. To date, no increased incidence of prostate cancer or any other type of human malignancy has been detected by Novartis in patients exposed to imatinib. 
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